Dr Reddy’s Laboratories has acquired rights to Haleon’s nicotine replacement therapy product portfolio outside of the US as part of a £500m ($632m) deal, marking a further expansion of Dr Reddy’s beyond pharmaceuticals.
Dr Reddy’s Acquires Nicotinell In A £500m Deal
The Acquistion Marks Another Step In The Company’s Diversified Strategy
The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.
More from Deals
More from Business
While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.
At the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor commented on the “offensively” low pricing for antibiotics in the US – “less than a packet of M&Ms” – while also revealing that the firm has struck a deal with a US PBM for its Samsung Bioepis-partnered Pyzchiva ustekinumab biosimilar to Stelara.
Adding to five new clinical trials launched in 2024, Xentria is doubling down on its ambitions in the biosimilars arena with up to six further studies in the coming year.